NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
about
Cost-Effectiveness of Disease-Modifying Therapies in Multiple SclerosisPractices and impact of primary outcome adjustment in randomized controlled trials: meta-epidemiologic studyClinical experience with repository corticotropin injection in patients with multiple sclerosis experiencing mood changes with intravenous methylprednisolone: a case seriesRelating relapse and T2 lesion changes to disability progression in multiple sclerosis: a systematic literature review and regression analysisNeuroendocrine immunoregulation in multiple sclerosisEndogenous and recombinant type I interferons and disease activity in multiple sclerosisCurrent and emerging therapies in multiple sclerosis: a systematic reviewEvaluating the Role of Corticosteroid Pulse Therapy in Patients With Secondary Progressive Multiple Sclerosis Receiving Mitoxantrone: A Double Blind Randomized Controlled Clinical Trial.Adrenocorticotropic hormone versus methylprednisolone added to interferon β in patients with multiple sclerosis experiencing breakthrough disease: a randomized, rater-blinded trialDisease-modifying agents in multiple sclerosis.Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.Disease-modifying therapies in relapsing-remitting multiple sclerosis.New approaches in the management of multiple sclerosis.Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial.The interferon beta therapies for treatment of relapsing-remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alonInterferon beta and glatiramer acetate therapy.Principles of a new treatment algorithm in multiple sclerosis.The neuroendocrine control of the innate immune system in health and brain diseases.Immunotherapy of multiple sclerosis: the state of the art.Minocycline added to subcutaneous interferon β-1a in multiple sclerosis: randomized RECYCLINE study.Vascular comorbidities in multiple sclerosis: a nationwide study from Denmark.Short-term, high-dose glucocorticoid treatment does not contribute to reduced bone mineral density in patients with multiple sclerosis.The impact of drugs for multiple sclerosis on sleep.Pharmacoeconomics and clinical trials in multiple sclerosis: baseline data from the European UnionMedication Treatment in Multiple Sclerosis
P2860
Q22252598-16D1796B-C6C4-4B36-A646-D9875990BC8AQ24289045-620C5C11-6A5B-4E9B-A86D-D31AB6E8D30DQ26748598-30203C5C-D159-496E-B1A5-53E1585D5BC7Q26828463-3D5CFEAF-A8A4-4318-A133-0C3FAF443DAFQ26864449-F5A721FA-ED17-416A-AE76-A8427CB89740Q28728759-B0D8629C-630E-43D0-A687-17B8D66AE94AQ29010983-F32FA091-5E54-41BE-9992-2E13673FC2A6Q31023281-F488AC76-A365-465F-A7E9-6EE1159D023DQ33589934-AF915693-0B5A-4A41-AC6F-C8AA7A18B8E7Q33670940-1FBFBB57-BEE0-444F-AF92-C8E00C134652Q34028864-565C6AC2-3843-4A86-B034-CBDEB84DFF81Q34122924-703CB28B-00AC-4B50-804E-417BB70BDD0DQ34389528-90A74ECA-5D17-438D-A8EF-798905A8CB0FQ35190771-30A2C7BB-E604-4866-8B67-44455FA29EC8Q35276609-6687450B-C6E5-405F-9402-895C1B62B7B5Q36568660-A8CA66F9-8E32-42EB-ACF8-5E4ACF2877FAQ37849763-3D4DF0A3-DF64-470C-B7A2-8550FE4B1D3AQ38020956-5A2CEFFD-AF8E-4144-81FA-9BE2C7BD3C0FQ38083041-D2F029C0-9C9C-4050-965B-BD4AEA7B0FE1Q40020998-960C250C-62DF-460C-AF13-7B332B1B6CDBQ40555407-3DF36C97-2269-4B5C-B728-30A6707B97FAQ41523600-332E6F2C-74BC-4C94-9B23-98647778F263Q47827946-80508825-C29A-4B6B-84EC-D53001C5BDCEQ56698309-896C4C76-B7B8-4CDA-88F0-EA44C110FD87Q57083576-FB464475-B8BC-445C-AAAF-08305F493742
P2860
NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
NORdic trial of oral Methylpre ...... sed, placebo-controlled trial.
@en
NORdic trial of oral Methylpre ...... sed, placebo-controlled trial.
@nl
type
label
NORdic trial of oral Methylpre ...... sed, placebo-controlled trial.
@en
NORdic trial of oral Methylpre ...... sed, placebo-controlled trial.
@nl
prefLabel
NORdic trial of oral Methylpre ...... sed, placebo-controlled trial.
@en
NORdic trial of oral Methylpre ...... sed, placebo-controlled trial.
@nl
P2093
P50
P921
P1433
P1476
NORdic trial of oral Methylpre ...... sed, placebo-controlled trial.
@en
P2093
Antonie Giaever Beiske
Inge Christoffer Olsen
Irina Elovaara
Jette Lautrup Frederiksen
Lise Vejby Søgaard
Magnhild Sandberg-Wollheim
Svein Ivar Mellgren
P304
P356
10.1016/S1474-4422(09)70085-7
P577
2009-05-04T00:00:00Z